Immunotherapy for Alzheimer's disease - PubMed (original) (raw)

Review

Immunotherapy for Alzheimer's disease

D Morgan. J Intern Med. 2011 Jan.

Abstract

In the year 1999, a vaccine approach was found to reduce amyloid deposits in transgenic mice overproducing the amyloid precursor protein. This was followed closely by demonstrations that vaccines or passive immunotherapy could rescue memory deficits in these mice. Initial human clinical trials revealed apparent autoimmune reactions in a subset of patients, but also some cases of cognitive benefit and amyloid clearance. Further work with passive immunotherapy in mouse models confirmed exceptional clearing abilities of anti-amyloid antibodies even in older mice. However, in parallel with parenchymal amyloid clearance was the appearance of microhaemorrhages and increased vascular amyloid deposition. Additional clinical trials with passive immunotherapy confirmed occasional appearance of microhaemorrhage and occurrence of vasogenic oedema in some patients, particularly those with the apolipoprotein E4 genotype. Recent data with positron emission tomography demonstrates trial participants passively immunized with anti-Aß antibodies have reduced signals with amyloid binding ligands after 18 months of therapy. Several anti-Aß immunotherapies have reached phase 3 testing, and immunotherapy is likely to be the first test of the amyloid hypothesis of Alzheimer's disease. Identifying antibody variants that retain amyloid clearance with fewer adverse reactions remains a major focus of translational research in this area.

© 2010 The Association for the Publication of the Journal of Internal Medicine.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest. In the past decade Dr Morgan has consulted with the following pharmaceutical companies on issues related to Alzheimer’s Immunotherapy. Pfizer, Wyeth, Rinat Neuroscience, Merck, Astra-Zeneca, Bristol-Myers-Squibb, Eisai, Forest, Lundbeck, Neurimmune, Elan and Baxter. Dr Morgan does not have current research support from any of the above mentioned companies.

Figures

Figure 1

Figure 1

Opsonization and Phagocytosis. Anti-Aβ antibodies bind to Aβ aggregates within the CNS. The immune complex then stimulates phagocytosis by Fc-gamma receptor bearing macrophages. The ingested Aβ is then digested and/or exported from the CNS. Reprinted from Ugen, K. and Morgan, D. DNA and Cell Biology 20:677–678

Figure 2

Figure 2

Peripheral Sink. Circulating anti-Aβ antibodies bind free Aβ in the blood and increase the efflux of Aβ down its concentration gradient and/or block the influx of Aβ from the circulation and back into the brain. Reprinted from Ugen, K. and Morgan, D. DNA and Cell Biology 20:677–678

Figure 3

Figure 3

Catalytic Modification of Conformation. Antibody binds Aβ and modifies the secondary structure to one which minimizes the formation of aggregates. Reprinted from Ugen, K. and Morgan, D. DNA and Cell Biology 20:677–678

Similar articles

Cited by

References

    1. DeKosky ST, Harbaugh RE, Schmitt FA, et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. AnnNeurol. 1992;32:625–32. - PubMed
    1. Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets. 2009;8:144–59. - PMC - PubMed
    1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6. - PubMed
    1. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469–75. - PMC - PubMed
    1. Mintun MA, Vlassenko A, Sheline YI, Morris JC. Longitudinal PIB PET imaging of the appearance and accumulation of beta-amyloid in cognitively normal middle and late life adults. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2010;6:S2.

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources